Basic Stats
| LEI | 5493000HLYOYQU6LK133 |
| CIK | 1801170 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Clover Health Investments, Corp.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Num |
|
| August 11, 2025 |
a8-kxex991x8112025 |
|
| August 11, 2025 |
Exhibit 99.2 Executive Chairperson's Q&A At Clover, we recently started addressing shareholder questions. I've taken a look through the submissions for this quarter and there are a couple of additional questions that I think are worth asking. So as the Company's largest shareholder I'll ask those questions below, and also answer them as well :-) Question 1: Why has Clover been able to financially |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| August 5, 2025 |
Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth •Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year •Second quarter 2025 Total revenues of $478 million, up 34% year-over-year •Second quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: •Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpoint •Maintains Insurance revenue between $1. |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number |
|
| May 14, 2025 |
First Quarter 2025 Shareholder Q&A Clover Health (Nasdaq: CLOV) First Quarter 2025 Shareholder Q&A May 14, 2025 In the lead-up to our first quarter 2025 earnings, we asked our shareholders to submit questions—anything from big-picture strategy to the mechanics of how we operate. |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| May 6, 2025 |
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance •First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year •First quarter 2025 Total revenues of $462 million, up 33% year-over-year •Medicare Advantage medical costs are in line with expectations, underscoring the strength of Clover’s technology-first care management model •Meaningful im |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number) |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2) |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| April 22, 2025 |
Clover Health Announces Changes to Board of Directors Clover Health Announces Changes to Board of Directors Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders’ Meeting WILMINGTON, Del. – April 22, 2025 – Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today annou |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| March 7, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| March 7, 2025 |
As filed with the Securities and Exchange Commission on March 7, 2025 As filed with the Securities and Exchange Commission on March 7, 2025 Registration No. |
|
| March 3, 2025 |
SUBSIDIARIES OF CLOVER HEALTH INVESTMENTS, CORP. Name of Subsidiary Jurisdiction of Organization Character Biosciences, Inc. Delaware Clover Cares Services of NJ, LLC New Jersey Clover Health HK Limited Hong Kong Clover Health Holdings, Inc. Delaware Clover Health International, Corp. Delaware Clover Health Labs, LLC California Clover Health Partners MSSP A, LLC Delaware Clover Health Partners MSS |
|
| March 3, 2025 |
CLOVER HEALTH INVESTMENTS, CORP. INSIDER TRADING POLICY (Amended and Restated as of February 13, 2025) 1. Purpose The following sets forth the policy of Clover Health Investments, Corp. (the “Company”) with respect to transactions in the Company’s securities (e.g., Class A common stock, Class B common stock, and stock options, but as described more fully in Section 4 below), as well as the securit |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| February 27, 2025 |
Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: •Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpoint •Insurance revenue between $1. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File N |
|
| January 13, 2025 |
JP Morgan Presentation 2025 January 2025 Slide Deck vF For 8-K / IR Site LGTMs: Date: Peter K. |
|
| January 13, 2025 |
Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period •Robust plan benefits powered member growth, mainly driven by switchers from other plans •Company will focus on balancing profitability with strategic investments in growth and technology to take advantage of strong market opportunity •~95% of Clover’s January 1, 2025 membership is in its flagship 4 Star PPO plan Wilmington, DE, January 13, 2025 – Clover Health Investments, Corp. |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| November 8, 2024 |
, 2024, between the Registrant and Peter Kuipers 1 CONFIDENTIAL April 15, 2024 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Peter Kuipers, This Employment Agreement (the “Agreement”) between you (referred to hereinafter as the “Executive”) and Clover Health Labs, LLC (the “Company”) sets forth the terms and conditions that shall govern Executive’s employment with the Company (refer |
|
| November 6, 2024 |
Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| October 10, 2024 |
Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025 Clover Health PPO Medicare Advantage Plans Earn 4 Star Rating for 2025 Overall Star rating performance increase was driven by exceptional performance on healthcare quality measures, Medication Adherence and Member Experience FRANKLIN, Tenn. |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File |
|
| August 22, 2024 |
Thomas L. Tran, Former Chief Financial Officer of Molina Healthcare, Joins Clover Health’s Board of Directors FRANKLIN, Tenn. – August 22, 2024 – Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. T |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Num |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| August 5, 2024 |
Clover Health Reports Second Quarter 2024 Financial Results; Improves Full-Year Guidance on Strong Performance Total Revenue growth for the Second Quarter of 2024 of 11% year-over-year GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of $7. |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| July 19, 2024 |
UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE YUECHUAN SUN, derivatively on behalf of CLOVER HEALTH INVESTMENTS, CORP. |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| June 26, 2024 |
Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement Exhibit 99.1 Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement FRANKLIN, Tenn. – June 26, 2024 – Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has received formal notice from The Nasdaq S |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| June 25, 2024 |
Exhibit 3.1 CLOVER HEALTH INVESTMENTS, CORP. (a Delaware corporation) SECOND AMENDED AND RESTATED BYLAWS As Adopted and Effective June 19, 2024 TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Annual Meetings 1 1.2 Special Meetings 1 1.3 Notice of Meetings 1 1.4 Adjournments 1 1.5 Quorum 2 1.6 Organization 2 1.7 Voting; Proxies 2 1.8 Fixing Date for Determination of Stockholders of Record 3 1.9 |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| June 14, 2024 |
CMS Improves Star Ratings to 3.5 Stars for Clover Health PPO Medicare Advantage Plans for 2025 Payment Year The Company previously communicated that CMS had calculated a rating of 3.0 Stars for its PPO plans, impacting payment year 2025. As a result of a recent rating recalculation, CMS has improved that rating to 3.5 Stars for 2025 payment year. FRANKLIN, Tenn. – June 14, 2024 – Clover Health Inv |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| May 29, 2024 |
exhibit992-cloverhealthi Clover Health 2024 Leerink Partners Healthcare Crossroads Conference May 2024 2 Disclaimer Please note that this presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. |
|
| May 29, 2024 |
Clover Health Announces Counterpart Health, a New SaaS and Tech Enabled Services Solution to Bring the Power of CA Technology to all Medicare Advantage Payors and Providers FRANKLIN, Tenn. |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number) |
|
| May 7, 2024 |
Clover Health Reports Strong First Quarter 2024 Financial Results; Improves Guidance to Target Full-Year 2024 Adjusted EBITDA Profitability First Quarter 2024 Insurance Revenue growth of 8% year-over-year First Quarter 2024 GAAP Net Loss from Continuing Operations of $23. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| May 7, 2024 |
Amended and Restated Director Compensation Policy CLOVER HEALTH INVESTMENTS, CORP. AMENDED AND RESTATED DIRECTOR COMPENSATION POLICY (Adopted, approved, and effective on June 21, 2023) Each member of the Board of Directors (the “Board”) of Clover Health Investments, Corp. (the “Company”) who is not an employee of the Company (each such member, an “Outside Director”) will receive the compensation described in this amended and restated Outside Dire |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2) |
|
| April 22, 2024 |
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer Franklin, Tenn. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| April 4, 2024 |
Clover Health Provides Notice Associated with Previously Disclosed Settlement of Shareholder Derivative Actions Franklin, TN – April 4, 2024 – As previously disclosed, most recently in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023, Clover Health Investments, Corp. |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| April 4, 2024 |
ex993-longxformnotice UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE YUECHUAN SUN, derivatively on behalf of CLOVER HEALTH INVESTMENTS, CORP. |
|
| April 4, 2024 |
ex992-stipulationofsettl UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF TENNESSEE YUECHUAN SUN, derivatively on behalf of CLOVER HEALTH INVESTMENTS, CORP. |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| March 14, 2024 |
Employment Agreement, dated as of March 8, 2024, between the Registrant and Karen Soares. CONFIDENTIAL March 8, 2024 Clover Health Investments, Corp. 725 Cool Springs Blvd, Suite 300 Franklin, Tennessee 37067 Re: EMPLOYMENT AGREEMENT Dear Karen Soares, This Employment Agreement (this “Agreement”) between you (referred to hereinafter as “Executive”) and Clover Health Labs (the “Company”) sets forth the terms and conditions that shall govern Executive’s employment with the Company (refer |
|
| March 14, 2024 |
SUBSIDIARIES OF CLOVER HEALTH INVESTMENTS, CORP.* Name of Subsidiary Jurisdiction of Organization Clover Health Labs, LLC California Clover Health Holdings, Inc. Delaware Clover Health Partners, LLC Delaware Clover Health, LLC New Jersey Clover HMO of New Jersey Inc. New Jersey Clover Insurance Company New Jersey Medical Service Professionals of NJ LLC New Jersey Juxly, LLC Missouri * The names of |
|
| March 14, 2024 |
December 22, 2023 Mr. Andrew Toy Chief Executive Officer Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, TN 37067 Re: Agreement for Interim Management Services Dear Mr. Toy: This letter, together with the attached Schedule(s) and General Terms and Conditions, sets forth the agreement (“Agreement”) between AP Services, LLC (“APS”), and Clover Health investments Corp. (the “C |
|
| March 14, 2024 |
December 22, 2023 Mr. Andrew Toy Chief Executive Officer Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, TN 37067 Re: Agreement for Interim Management Services Dear Mr. Toy: This letter, together with the attached Schedule(s) and General Terms and Conditions, sets forth the agreement (“Agreement”) between AP Services, LLC (“APS”), and Clover Health investments Corp. (the “C |
|
| March 14, 2024 |
Clover Health Investments, Corp. Clawback Policy CLOVER HEALTH INVESTMENTS, CORP. CLAWBACK POLICY Adopted March 22, 2023 This clawback policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Clover Health Investments, Corp. (the “Company”) to provide for the recoupment of certain executive compensation in the event of either an accounting restatement or certain types of misconduct. The Talent and Compensation Committee |
|
| March 14, 2024 |
Clover Health Investments, Corp. Clawback Policy CLOVER HEALTH INVESTMENTS, CORP. CLAWBACK POLICY Adopted March 22, 2023 This clawback policy (the “Policy”) has been adopted by the Board of Directors (the “Board”) of Clover Health Investments, Corp. (the “Company”) to provide for the recoupment of certain executive compensation in the event of either an accounting restatement or certain types of misconduct. The Talent and Compensation Committee |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| March 12, 2024 |
Clover Health Reports Fourth Quarter and Full Year 2023 Financial Results; Delivers Continued Momentum in Financial Performance and Provides Full-Year 2024 Guidance Full-year 2023 Insurance MCR improved to 81. |
|
| March 12, 2024 |
Clover Health Reports Fourth Quarter and Full Year 2023 Financial Results; Delivers Continued Momentum in Financial Performance and Provides Full-Year 2024 Guidance Full-year 2023 Insurance MCR improved to 81. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| February 13, 2024 |
CLOV / Clover Health Investments, Corp. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0628-cloverhealthinvestmen.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Clover Health Investments Corp. Class A Title of Class of Securities: Common Stock CUSIP Number: 18914F103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the ap |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| January 10, 2024 |
cloverhealthinvestorpres Clover Health J.P. Morgan Healthcare Conference January 2024 2 Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including statements regarding future events including, without limitation, Clover Health Investments, Corp.’s (“Clover Health,” “we,” “our,” or “us”), expectations regarding positive Adjusted EBITDA (a non-G |
|
| January 10, 2024 |
cloverhealthinvestorpres Clover Health J.P. Morgan Healthcare Conference January 2024 2 Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including statements regarding future events including, without limitation, Clover Health Investments, Corp.’s (“Clover Health,” “we,” “our,” or “us”), expectations regarding positive Adjusted EBITDA (a non-G |
|
| January 10, 2024 |
Clover Health Provides Business Update and Full-Year 2024 Objectives Clover Health Provides Business Update and Full-Year 2024 Objectives FRANKLIN, Tenn. |
|
| January 10, 2024 |
Clover Health Provides Business Update and Full-Year 2024 Objectives Clover Health Provides Business Update and Full-Year 2024 Objectives FRANKLIN, Tenn. |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File N |
|
| December 21, 2023 |
Clover Health Announces Departure of Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for 2023 Lee A. |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File N |
|
| December 21, 2023 |
Clover Health Announces Departure of Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for 2023 Lee A. |
|
| December 1, 2023 |
Clover Health Exits ACO REACH to Accelerate Path to Profitability Clover Health Exits ACO REACH to Accelerate Path to Profitability FRANKLIN, Tenn., December 1, 2023–Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has delivered notice to the Centers for Medicare and Medicaid Services (“CMS” |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File N |
|
| December 1, 2023 |
Clover Health Exits ACO REACH to Accelerate Path to Profitability Clover Health Exits ACO REACH to Accelerate Path to Profitability FRANKLIN, Tenn., December 1, 2023–Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has delivered notice to the Centers for Medicare and Medicaid Services (“CMS” |
|
| November 6, 2023 |
Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance Q3 2023 Insurance MCR Improved to 78. |
|
| November 6, 2023 |
Clover Health Reports Third Quarter 2023 Results; Highlights Continued Improvement in Financial Performance and Improved 2023 Guidance Q3 2023 Insurance MCR Improved to 78. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q clover?fl2w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Num |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| August 8, 2023 |
Clover Health Reports Strong Second Quarter 2023 Results; Highlights Improved Financial Performance and Guidance Ranges Insurance revenue grew 17% compared to Q2'22, and second quarter Insurance MCR improved to 77. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q fl2w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| August 8, 2023 |
Clover Health Reports Strong Second Quarter 2023 Results; Highlights Improved Financial Performance and Guidance Ranges Insurance revenue grew 17% compared to Q2'22, and second quarter Insurance MCR improved to 77. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| August 3, 2023 |
Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement FRANKLIN, Tenn. |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| August 3, 2023 |
Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement FRANKLIN, Tenn. |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| June 22, 2023 |
Clover Health Announces Agreement to Settle Derivative Litigation, Resolving All Remaining Civil Litigation Relating to its de-SPAC Transaction June 22, 2023 FRANKLIN, Tenn. |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| June 22, 2023 |
Clover Health Announces Agreement to Settle Derivative Litigation, Resolving All Remaining Civil Litigation Relating to its de-SPAC Transaction June 22, 2023 FRANKLIN, Tenn. |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number |
|
| May 9, 2023 |
Preferability letter from Ernst & Young LLP regarding change in accounting principle May 9, 2023 Board of Directors Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, Tennessee, 37067 Ladies and Gentlemen: Note 2 to the Notes to the consolidated financial statements of Clover Health Investments, Corp. included in its Form 10-Q for the period ended March 31, 2023, describes a change in the method of accounting for premium deficiency reserves to include anticipa |
|
| May 9, 2023 |
Employment Agreement, dated as of February 24, 2022, between the Registrant and Conrad Wai Certain identified information has been excluded from this exhibit because it is not material and is the type of information that the Registrant customarily and actually treats as private and confidential. |
|
| May 9, 2023 |
Clover Health Reports First Quarter 2023 Financial Results Insurance revenue grew by 14% over Q1’22 Insurance and Non-Insurance MCR improved to 86. |
|
| May 9, 2023 |
Clover Health Reports First Quarter 2023 Financial Results Insurance revenue grew by 14% over Q1’22 Insurance and Non-Insurance MCR improved to 86. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q fl2w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| May 9, 2023 |
Preferability letter from Ernst & Young LLP regarding change in accounting principle May 9, 2023 Board of Directors Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, Tennessee, 37067 Ladies and Gentlemen: Note 2 to the Notes to the consolidated financial statements of Clover Health Investments, Corp. included in its Form 10-Q for the period ended March 31, 2023, describes a change in the method of accounting for premium deficiency reserves to include anticipa |
|
| May 9, 2023 |
Employment Agreement, dated as of February 24, 2022, between the Registrant and Conrad Wai Certain identified information has been excluded from this exhibit because it is not material and is the type of information that the Registrant customarily and actually treats as private and confidential. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number) |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as Permitted by Rule 14A-6(e)(2 |
|
| April 24, 2023 |
Clover Health Announces Agreement to Settle Securities Class Action Litigation Clover Health Announces Agreement to Settle Securities Class Action Litigation April 24, 2023 FRANKLIN, Tenn. |
|
| April 24, 2023 |
Clover Health Announces Agreement to Settle Securities Class Action Litigation Clover Health Announces Agreement to Settle Securities Class Action Litigation April 24, 2023 FRANKLIN, Tenn. |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| April 20, 2023 |
Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability April 17, 2023 Net annualized savings from initiatives expected to be approximately $30 million beginning in 2024 FRANKLIN, Tenn. |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| April 20, 2023 |
Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability Clover Health Announces Business Transformation Initiatives to Accelerate Path to Profitability April 17, 2023 Net annualized savings from initiatives expected to be approximately $30 million beginning in 2024 FRANKLIN, Tenn. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| March 17, 2023 |
Board Observer Agreement, dated as of March 16, 2023, between the Registrant and Zach Weinberg. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. |
|
| March 9, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| March 9, 2023 |
Power of Attorney (included on the signature page of this Registration Statement) As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| March 1, 2023 |
Employment Agreement, dated as of July 18, 2022, between the Registrant and Brady Priest CONFIDENTIAL June 28, 2022 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Brady Priest, This Employment Agreement (the “Agreement”) between you (referred to hereinafter as the “Executive”) and Clover Health Labs, LLC (the “Company”) sets forth the terms and conditions that shall govern Executive’s employment with the Company (referred |
|
| March 1, 2023 |
CLOVER HEALTH INVESTMENTS, CORP. February 23, 2023 Mr. Prabhdeep Singh Dear Prabhdeep: This letter (the “Agreement”) confirms the agreement between you and Clover Health Investments, Corp. (collectively, with its affiliates and subsidiaries, the “Company”) regarding the termination of your employment with the Company. 1.Separation Date. By signing this Agreement, you hereby agree to resign, effect |
|
| March 1, 2023 |
Employment Agreement, dated as of July 18, 2022, between the Registrant and Brady Priest CONFIDENTIAL June 28, 2022 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Brady Priest, This Employment Agreement (the “Agreement”) between you (referred to hereinafter as the “Executive”) and Clover Health Labs, LLC (the “Company”) sets forth the terms and conditions that shall govern Executive’s employment with the Company (referred |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K fl2w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| March 1, 2023 |
Exhibit 21.1 SUBSIDIARIES OF CLOVER HEALTH INVESTMENTS, CORP. Name of Subsidiary Jurisdiction of Organization Clover Health Labs, LLC California Clover Health International, Corp. Delaware Clover Health Corp. Delaware Clover Health Holdings, Inc. Delaware Clover Health Partners, LLC Delaware Clover HMO Corp. Delaware Principium Health, LLC Delaware Clover Health HK Limited Hong Kong Clover Healthc |
|
| March 1, 2023 |
Exhibit 21.1 SUBSIDIARIES OF CLOVER HEALTH INVESTMENTS, CORP. Name of Subsidiary Jurisdiction of Organization Clover Health Labs, LLC California Clover Health International, Corp. Delaware Clover Health Corp. Delaware Clover Health Holdings, Inc. Delaware Clover Health Partners, LLC Delaware Clover HMO Corp. Delaware Principium Health, LLC Delaware Clover Health HK Limited Hong Kong Clover Healthc |
|
| March 1, 2023 |
CLOVER HEALTH INVESTMENTS, CORP. February 23, 2023 Mr. Prabhdeep Singh Dear Prabhdeep: This letter (the “Agreement”) confirms the agreement between you and Clover Health Investments, Corp. (collectively, with its affiliates and subsidiaries, the “Company”) regarding the termination of your employment with the Company. 1.Separation Date. By signing this Agreement, you hereby agree to resign, effect |
|
| February 28, 2023 |
Clover Health Reports Fourth Quarter and Full Year 2022 Financial Results Q4 2022 Insurance MCR of 92. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File N |
|
| February 28, 2023 |
Clover Health Reports Fourth Quarter and Full Year 2022 Financial Results Q4 2022 Insurance MCR of 92. |
|
| February 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Clover Health Investments Corp. Class A Title of Class of Securities: Common Stock CUSIP Number: 18914F103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| January 10, 2023 |
cloverhealthinvestorpres Clover Health J.P. Morgan Healthcare Conference January 11, 2023 2 This presentation and the accompanying oral presentation include forward-looking statements, including statements regarding future events and Clover Health Investments, Corp.’s (“Clover,” “we,” “our,” or “us”) future results of operations, financial position, business strategy and future plans, and the fact |
|
| January 10, 2023 |
cloverhealthprovidesbusi Clover Health Provides Business Update and Issues Partial Guidance for Full-Year 2023 FRANKLIN, Tenn. |
|
| January 10, 2023 |
cloverhealthinvestorpres Clover Health J.P. Morgan Healthcare Conference January 11, 2023 2 This presentation and the accompanying oral presentation include forward-looking statements, including statements regarding future events and Clover Health Investments, Corp.’s (“Clover,” “we,” “our,” or “us”) future results of operations, financial position, business strategy and future plans, and the fact |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Num |
|
| January 10, 2023 |
cloverhealthprovidesbusi Clover Health Provides Business Update and Issues Partial Guidance for Full-Year 2023 FRANKLIN, Tenn. |
|
| November 30, 2022 |
Dr. Anna Loengard Joins Clover Health Board of Directors Dr. Anna Loengard Joins Clover Health Board of Directors FRANKLIN, Tenn. – November 30, 2022 – Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Anna Loengard, M.D. to the Company’s Board of Directors. Dr. Loengard is a highly accomplished |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File N |
|
| November 30, 2022 |
Dr. Anna Loengard Joins Clover Health Board of Directors Dr. Anna Loengard Joins Clover Health Board of Directors FRANKLIN, Tenn. – November 30, 2022 – Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Anna Loengard, M.D. to the Company’s Board of Directors. Dr. Loengard is a highly accomplished |
|
| November 22, 2022 |
CLOVER HEALTH INVESTMENTS, CORP. CORRESP 1 filename1.htm CLOVER HEALTH INVESTMENTS, CORP. November 22, 2022 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Clover Health Investments, Corp. Form 10-K for the Fiscal Year Ended December 31, 2021 Form 10-Q for the Quarterly Period Ended September 30, 2022 Response dated September 28, 2022 File No |
|
| November 7, 2022 |
Clover Health Reports Third Quarter 2022 Financial Results Third quarter Insurance MCR of 86. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 2w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| November 7, 2022 |
Amended and Restated Director Compensation Policy CLOVER HEALTH INVESTMENTS, CORP. AMENDED AND RESTATED DIRECTOR COMPENSATION POLICY (Adopted, approved, and effective on September 21, 2022) Each member of the Board of Directors (the “Board”) of Clover Health Investments, Corp. (the “Company”) who is not an employee of the Company (each such member, an “Outside Director”) will receive the compensation described in this amended and restated Outside |
|
| November 7, 2022 |
Amended and Restated Director Compensation Policy CLOVER HEALTH INVESTMENTS, CORP. AMENDED AND RESTATED DIRECTOR COMPENSATION POLICY (Adopted, approved, and effective on September 21, 2022) Each member of the Board of Directors (the “Board”) of Clover Health Investments, Corp. (the “Company”) who is not an employee of the Company (each such member, an “Outside Director”) will receive the compensation described in this amended and restated Outside |
|
| November 7, 2022 |
Clover Health Reports Third Quarter 2022 Financial Results Third quarter Insurance MCR of 86. |
|
| November 7, 2022 |
Employment Agreement, dated as of August 8, 2022, between the Registrant and Andrew Toy FINAL CONFIDENTIAL August 8, 2022 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Andrew Toy, This Employment Agreement (the “Agreement”) between you (referred to hereinafter as “Executive”) and Clover Health, LLC (the “Company”) sets forth the terms and conditions that shall govern Executive’s employment with the Company (referred to h |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* CLOVER HEALTH INVESTMENTS, CORP. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 18914F111 (CUSIP Number) Chamath Palihapitiya 506 Santa Cruz Avenue, Suite 300 Menlo Park, California 94025 (650) 521-9007 (Name, Address and Telephone |
|
| September 28, 2022 |
CLOVER HEALTH INVESTMENTS, CORP. CLOVER HEALTH INVESTMENTS, CORP. September 28, 2022 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Clover Health Investments, Corp. Form 10-K for the Fiscal Year Ended December 31, 2021 Form 10-Q for the Quarterly Period Ended June 30, 2022 Form 8-K filed August 8, 2022 File No. 001-39252 Ladies and Gentlemen |
|
| September 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ????????? ??Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission Only (as Permitted By Rule 14A-6(e)(2 |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ????????? ??Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission Only (as Permitted By Rule 14A-6(e)(2 |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| August 8, 2022 |
Employment Agreement, effective as of May 9, 2022, between the Registrant and Aric Sharp CONFIDENTIAL Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Aric Sharp, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employment with the Company (referred to hereinafter as ?Em |
|
| August 8, 2022 |
Employment Agreement, effective as of May 9, 2022, between the Registrant and Aric Sharp CONFIDENTIAL Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Aric Sharp, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employment with the Company (referred to hereinafter as ?Em |
|
| August 8, 2022 |
Employment Agreement, dated as of May 11, 2022, between the Registrant and Scott J. Leffler CONFIDENTIAL May 11, 2022 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Scott Leffler, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employment with the Company (referred to he |
|
| August 8, 2022 |
Clover Health Reports Second Quarter 2022 Financial Results Second quarter total revenue was $846. |
|
| August 8, 2022 |
Clover Health Reports Second Quarter 2022 Financial Results Second quarter total revenue was $846. |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numb |
|
| August 8, 2022 |
Employment Agreement, dated as of May 11, 2022, between the Registrant and Scott J. Leffler CONFIDENTIAL May 11, 2022 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin TN 37067 Re: EMPLOYMENT AGREEMENT Dear Scott Leffler, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employment with the Company (referred to he |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q I I ???2w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| July 26, 2022 |
Dr. Carladenise Armbrister Edwards Joins Clover Health Board of Directors EXHIBIT 99.1 Dr. Carladenise Armbrister Edwards Joins Clover Health Board of Directors FRANKLIN, Tenn. ? July 26, 2022 ? Clover Health Investments, Corp. (NASDAQ: CLOV) (?Clover,? ?Clover Health? or the ?Company?), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Carladenise Armbrister Edwards, Ph.D., to the Company?s Board of Dire |
|
| July 26, 2022 |
Dr. Carladenise Armbrister Edwards Joins Clover Health Board of Directors EXHIBIT 99.1 Dr. Carladenise Armbrister Edwards Joins Clover Health Board of Directors FRANKLIN, Tenn. ? July 26, 2022 ? Clover Health Investments, Corp. (NASDAQ: CLOV) (?Clover,? ?Clover Health? or the ?Company?), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Carladenise Armbrister Edwards, Ph.D., to the Company?s Board of Dire |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Numbe |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number |
|
| May 25, 2022 |
Clover Health Appoints Scott J. Leffler as Chief Financial Officer Clover Health Appoints Scott J. Leffler as Chief Financial Officer FRANKLIN, Tenn., May 25, 2022 (GLOBE NEWSWIRE) - Clover Health Investments, Corp. (NASDAQ: CLOV) (?Clover? or ?Clover Health?), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Scott J. Leffler as Chief Financial Officer (?CFO?). He will join Clover in August 2022 a |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number |
|
| May 25, 2022 |
Clover Health Appoints Scott J. Leffler as Chief Financial Officer Clover Health Appoints Scott J. Leffler as Chief Financial Officer FRANKLIN, Tenn., May 25, 2022 (GLOBE NEWSWIRE) - Clover Health Investments, Corp. (NASDAQ: CLOV) (?Clover? or ?Clover Health?), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Scott J. Leffler as Chief Financial Officer (?CFO?). He will join Clover in August 2022 a |
|
| May 18, 2022 |
Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, Tennessee 37067 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, Tennessee 37067 May 18, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Clover Health Investments, Corp. Registration Statement on Form S-3 Filed May 9, 2022 File No. 333-264801 Ladies and Gentlemen: Pursuant to Rule |
|
| May 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Clover Health Investments, Corp. |
|
| May 9, 2022 |
entered into between the Company and Wilmington Trust, National Association, as Trustee Exhibit 4.3 CLOVER HEALTH INVESTMENTS, CORP. as the Company and WILMINGTON TRUST, NATIONAL ASSOCIATION as the Trustee Indenture Dated as of 1 TABLE OF CONTENTS Page ARTICLE 1 Definitions and Incorporation by Reference Section 1.01 Definitions. 1 Section 1.02 Other Definitions 5 Section 1.03 Incorporation by Reference of Trust Indenture Act 6 Section 1.04 Rules of Construction 6 ARTICLE 2 THE SECUR |
|
| May 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Clover Health Investments, Corp. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Number) |
|
| May 9, 2022 |
Employment Agreement, effective as of March 14, 2022, between the Registrant and Joseph Martin CONFIDENTIAL March 11, 2022 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, Tennessee 37067 Re: EMPLOYMENT AGREEMENT Dear Joseph Martin, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employment with the Company (refe |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q I I ???2w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| May 9, 2022 |
Employment Agreement, effective as of March 14, 2022, between the Registrant and Joseph Martin CONFIDENTIAL March 11, 2022 Clover Health Investments, Corp. 3401 Mallory Lane, Suite 210 Franklin, Tennessee 37067 Re: EMPLOYMENT AGREEMENT Dear Joseph Martin, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employment with the Company (refe |
|
| May 9, 2022 |
entered into between the Company and Wilmington Trust, National Association, as Trustee Exhibit 4.3 CLOVER HEALTH INVESTMENTS, CORP. as the Company and WILMINGTON TRUST, NATIONAL ASSOCIATION as the Trustee Indenture Dated as of 1 TABLE OF CONTENTS Page ARTICLE 1 Definitions and Incorporation by Reference Section 1.01 Definitions. 1 Section 1.02 Other Definitions 5 Section 1.03 Incorporation by Reference of Trust Indenture Act 6 Section 1.04 Rules of Construction 6 ARTICLE 2 THE SECUR |
|
| May 9, 2022 |
Clover Health Reports First Quarter 2022 Financial Results First quarter total revenue was $874. |
|
| May 9, 2022 |
Statement of Eligibility of Wilmington Trust, National Association, as Trustee, on Form T-1. Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-1486454 (I.R.S. employer identification no.) 1100 North Market Street Wilmington, DE 19890-0001 (Address of principal ex |
|
| May 9, 2022 |
Statement of Eligibility of Wilmington Trust, National Association, as Trustee, on Form T-1. Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-1486454 (I.R.S. employer identification no.) 1100 North Market Street Wilmington, DE 19890-0001 (Address of principal ex |
|
| May 9, 2022 |
Clover Health Reports First Quarter 2022 Financial Results First quarter total revenue was $874. |
|
| May 9, 2022 |
Registration No. 333- As filed with the Securities and Exchange Commission on May 9, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Clover Health Investments, Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 98-1515192 (I |
|
| March 10, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Clover Health Investments, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 18914F103 (CUSIP Number) February 28, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designa |
|
| March 9, 2022 |
Power of Attorney (included on the signature page of this Registration Statement) As filed with the Securities and Exchange Commission on March 9, 2022 Registration No. |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| March 9, 2022 |
Clover Health Investments, Corp. 2022 Inducement Award Plan Exhibit 99.1 CLOVER HEALTH INVESTMENTS, CORP. 2022 INDUCEMENT AWARD PLAN 1.Purposes of the Plan. The purpose of this Plan is to provide a mechanism to assist the Company in attracting the best available personnel by providing equity and equity-based awards to individuals as a material inducement to the individual accepting employment with the Company, thereby allowing the Company to build a strong |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| March 9, 2022 |
Power of Attorney (included in the signature pages to this Registration Statement) As filed with the Securities and Exchange Commission on March 9, 2022 Registration No. |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Clover Health Investments, Corp. |
|
| February 28, 2022 |
Employment Agreement, effective as of December 31, 2021, between the Registrant and Jamie L. Reynoso Exhibit 10.12 CONFIDENTIAL December 17, 2021 Clover Health Investments, Corp. 725 Cool Springs Blvd, Suite 300 Franklin, Tennessee 37067 Re: EMPLOYMENT AGREEMENT Dear Jamie Reynoso, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health Labs, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employm |
|
| February 28, 2022 |
Letter Agreement, dated January 19, 2022, between the Registrant and Gia Lee Exhibit 10.14 Execution Copy CLOVER HEALTH INVESTMENTS, CORP. January 19, 2022 Gia B. Lee, Esq. 3530 Springland Lane NW Washington, D.C. 20008 Dear Gia: This letter (the ?Agreement?) confirms the agreement between you and Clover Health Investments, Corp. (collectively, with its affiliates and subsidiaries, the ?Company?) regarding the conclusion of your employment with the Company. 1.Separation Da |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| February 28, 2022 |
between the Registrant and Prabhdeep Exhibit 10.13 Confidential CLOVER HEALTH INVESTMENTS, CORP. 725 Cool Springs Blvd, Suite 300 Franklin, Tennessee 37067 June 15, 2021 Re: EMPLOYMENT AGREEMENT Dear Prabhdeep: This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health Investments, Corp., a Delaware corporation (the ?Company?) sets forth the terms and conditions that shall g |
|
| February 28, 2022 |
Employment Agreement, effective as of December 31, 2021, between the Registrant and Jamie L. Reynoso Exhibit 10.12 CONFIDENTIAL December 17, 2021 Clover Health Investments, Corp. 725 Cool Springs Blvd, Suite 300 Franklin, Tennessee 37067 Re: EMPLOYMENT AGREEMENT Dear Jamie Reynoso, This Employment Agreement (the ?Agreement?) between you (referred to hereinafter as the ?Executive?) and Clover Health Labs, LLC (the ?Company?) sets forth the terms and conditions that shall govern Executive?s employm |
|
| February 28, 2022 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to the amended and restated certificate of incorporation (for purposes of this section, the ?charter?) and the amended and restated bylaws (for purposes of this section, the ?byla |
|
| February 28, 2022 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to the amended and restated certificate of incorporation (for purposes of this section, the ?charter?) and the amended and restated bylaws (for purposes of this section, the ?byla |
|
| February 28, 2022 |
Letter Agreement, dated January 19, 2022, between the Registrant and Gia Lee Exhibit 10.14 Execution Copy CLOVER HEALTH INVESTMENTS, CORP. January 19, 2022 Gia B. Lee, Esq. 3530 Springland Lane NW Washington, D.C. 20008 Dear Gia: This letter (the ?Agreement?) confirms the agreement between you and Clover Health Investments, Corp. (collectively, with its affiliates and subsidiaries, the ?Company?) regarding the conclusion of your employment with the Company. 1.Separation Da |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File N |
|
| February 23, 2022 |
Clover Health Reports Fourth Quarter 2021 Financial Results Fourth quarter total revenue was $432. |
|
| February 23, 2022 |
Clover Health Reports Fourth Quarter 2021 Financial Results Fourth quarter total revenue was $432. |
|
| February 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Clover Health Investments Corp. Class A Title of Class of Securities: Common Stock CUSIP Number: 18914F103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this |
|
| February 3, 2022 |
As filed with the Securities and Exchange Commission on February 2, 2022. As filed with the Securities and Exchange Commission on February 2, 2022. Registration No. 333-249558 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLOVER HEALTH INVESTMENTS, CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 6324 98-1515192 (S |
|
| February 3, 2022 |
As filed with the Securities and Exchange Commission on February 2, 2022. As filed with the Securities and Exchange Commission on February 2, 2022. Registration No. 333-252073 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLOVER HEALTH INVESTMENTS, CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 6324 98-1515192 (S |
|
| January 19, 2022 |
Clover Health Investments, Corp. Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-252073 and 333-249558 PROSPECTUS SUPPLEMENT NOS. 9 AND 8 (to Prospectuses dated June 25, 2021 and June 25, 2021) Clover Health Investments, Corp. This prospectus supplement updates and supplements the prospectuses dated June 25, 2021 and June 25, 2021 (the "Prospectuses"), which form a part of our registration statements on Form S-1 (No. 333-2 |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2022 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| January 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* CLOVER HEALTH INVESTMENTS, CORP. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 18914F111 (CUSIP Number) Chamath Palihapitiya SCH Sponsor III LLC 317 University Ave, Suite 200 Palo Alto, California 94301 (650) 521-9007 (Name, Addres |
|
| January 14, 2022 |
Exhibit 6 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D relating to the Class A common stock, par value $0. |
|
| January 14, 2022 |
Exhibit 6 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D relating to the Class A common stock, par value $0. |
|
| December 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Clover Health Investments, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 18914F103 (CUSIP Number) November 30, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designa |
|
| November 18, 2021 |
As filed with the Securities and Exchange Commission on November 17, 2021. POS EX 1 cloverhealthposex.htm POS EX As filed with the Securities and Exchange Commission on November 17, 2021. Registration No. 333- 261078 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLOVER HEALTH INVESTMENTS, CORP. (Exact Name of Registrant as Specified in Its Charter) |
|
| November 18, 2021 |
52,173,913 Shares Class A Common Stock Filed Pursuant to Rule 424(b)(4) File Nos. 333-261078 and 333-261160 52,173,913 Shares Class A Common Stock We are offering 52,173,913 shares of our Class A common stock. Our Class A common stock is listed on the Nasdaq Global Select Market (the ?Nasdaq?) under the symbol ?CLOV.? The market prices and trading volume of our shares of Class A common stock have experienced, and may continue to experi |
|
| November 17, 2021 |
As filed with the Securities and Exchange Commission on November 17, 2021. As filed with the Securities and Exchange Commission on November 17, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLOVER HEALTH INVESTMENTS, CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 6324 98-1515192 (State or Other Jurisdiction of Incorporation or Orga |
|
| November 15, 2021 |
VIA EDGAR November 15, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Clover Health Investments, Corp. Registration Statement on Form S-1 (File No. 333-261078) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the ?Act?), Citigroup Global Markets Inc. and Deutsche Bank Securiti |
|
| November 15, 2021 |
Exhibit 1.1 CLOVER HEALTH INVESTMENTS, CORP. [?] Shares of Common Stock Plus an option to purchase from the Company up to [?] additional Securities ($0.0001 par value) Underwriting Agreement New York, New York November [?], 2021 Citigroup Global Markets Inc. Deutsche Bank Securities Inc. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York |
|
| November 15, 2021 |
Exhibit 1.1 CLOVER HEALTH INVESTMENTS, CORP. [?] Shares of Common Stock Plus an option to purchase from the Company up to [?] additional Securities ($0.0001 par value) Underwriting Agreement New York, New York November [?], 2021 Citigroup Global Markets Inc. Deutsche Bank Securities Inc. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York |
|
| November 15, 2021 |
5401 Mallory Lane, Suite 210 Franklin, TN 37067 5401 Mallory Lane, Suite 210 Franklin, TN 37067 November 15, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: J. Nolan McWilliams Justin Dobbie Re: Clover Health Investments, Corp. Registration Statement on Form S-1 File No. 333-261078 REQUEST FOR ACCELERATION OF EFFECTIVENESS Acceleration Request Requested Date: |
|
| November 15, 2021 |
As filed with the Securities and Exchange Commission on November 15, 2021. As filed with the Securities and Exchange Commission on November 15, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLOVER HEALTH INVESTMENTS, CORP. (Exact Name of Registrant as Specified in Its Charter) Delaware 6324 98-1515192 (State or Other Jurisdiction of Incorporation or Orga |
|
| November 10, 2021 |
CORRESP 1 filename1.htm November 10, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: J. Nolan McWilliams Justin Dobbie Re: Clover Health Investments, Corp. Draft Registration Statement on Form S-1 Submitted August 13, 2021 CIK No. 0001801170 Ladies and Gentlemen: On behalf of Clover Health Inve |
|
| November 9, 2021 |
Letter Agreement dated as of August 13, 2021, by and between the Registrant and Joseph Wagner CLOVER HEALTH INVESTMENTS, CORP. August 12, 2021 Joseph Wagner Phoenix, MD 21131 Dear Joe: This letter (the ?Agreement?) confirms the agreement between you and Clover Health Investments, Corp. (the ?Company?) regarding the termination of your employment with the Company. 1. Separation Date. On July 9, 2021, you provided notice of your voluntary resignation from employment with the Company effectiv |
|
| November 9, 2021 |
Letter Agreement dated as of August 13, 2021, by and between the Registrant and Joseph Wagner CLOVER HEALTH INVESTMENTS, CORP. August 12, 2021 Joseph Wagner Phoenix, MD 21131 Dear Joe: This letter (the ?Agreement?) confirms the agreement between you and Clover Health Investments, Corp. (the ?Company?) regarding the termination of your employment with the Company. 1. Separation Date. On July 9, 2021, you provided notice of your voluntary resignation from employment with the Company effectiv |
|
| November 9, 2021 |
Mr. Vivek Garipalli July 12, 2021 Chief Executive Officer Clover Health Investments Corp. 725 Cool Sprigs Blvd., Suite 320 Franklin, TN 37067 Re: Agreement for the Provision of Interim Management Services Dear Mr. Garipalli: This letter, together with the attached Schedule(s) and General Terms and Conditions, sets forth the agreement (?Agreement?) between AP Services, LLC (?APS?), and Clover Healt |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39252 Clover Health Investments, Corp. |
|
| November 9, 2021 |
Mr. Vivek Garipalli July 12, 2021 Chief Executive Officer Clover Health Investments Corp. 725 Cool Sprigs Blvd., Suite 320 Franklin, TN 37067 Re: Agreement for the Provision of Interim Management Services Dear Mr. Garipalli: This letter, together with the attached Schedule(s) and General Terms and Conditions, sets forth the agreement (?Agreement?) between AP Services, LLC (?APS?), and Clover Healt |
|
| November 9, 2021 |
Clover Health Investments, Corp. Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-252073 and 333-249558 PROSPECTUS SUPPLEMENT NOS. 8 AND 7 (to Prospectuses dated June 25, 2021 and June 25, 2021) Clover Health Investments, Corp. This prospectus supplement updates and supplements the prospectuses dated June 25, 2021 and June 25, 2021 (the "Prospectuses"), which form a part of our registration statements on Form S-1 (No. 333-2 |
|
| November 9, 2021 |
Letter Agreement dated as of August 13, 2021, by and between the Registrant and Joseph Wagner CLOVER HEALTH INVESTMENTS, CORP. August 12, 2021 Joseph Wagner Phoenix, MD 21131 Dear Joe: This letter (the ?Agreement?) confirms the agreement between you and Clover Health Investments, Corp. (the ?Company?) regarding the termination of your employment with the Company. 1. Separation Date. On July 9, 2021, you provided notice of your voluntary resignation from employment with the Company effectiv |
|
| November 9, 2021 |
Mr. Vivek Garipalli July 12, 2021 Chief Executive Officer Clover Health Investments Corp. 725 Cool Sprigs Blvd., Suite 320 Franklin, TN 37067 Re: Agreement for the Provision of Interim Management Services Dear Mr. Garipalli: This letter, together with the attached Schedule(s) and General Terms and Conditions, sets forth the agreement (?Agreement?) between AP Services, LLC (?APS?), and Clover Healt |
|
| November 9, 2021 |
Letter Agreement dated as of August 13, 2021, by and between the Registrant and Joseph Wagner CLOVER HEALTH INVESTMENTS, CORP. August 12, 2021 Joseph Wagner Phoenix, MD 21131 Dear Joe: This letter (the ?Agreement?) confirms the agreement between you and Clover Health Investments, Corp. (the ?Company?) regarding the termination of your employment with the Company. 1. Separation Date. On July 9, 2021, you provided notice of your voluntary resignation from employment with the Company effectiv |
|
| November 9, 2021 |
Mr. Vivek Garipalli July 12, 2021 Chief Executive Officer Clover Health Investments Corp. 725 Cool Sprigs Blvd., Suite 320 Franklin, TN 37067 Re: Agreement for the Provision of Interim Management Services Dear Mr. Garipalli: This letter, together with the attached Schedule(s) and General Terms and Conditions, sets forth the agreement (?Agreement?) between AP Services, LLC (?APS?), and Clover Healt |
|
| November 8, 2021 |
Clover Health Reports Third Quarter 2021 Financial Results Total revenue was $427. |
|
| November 8, 2021 |
Clover Health Reports Third Quarter 2021 Financial Results Total revenue was $427. |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 CLOVER HEALTH INVESTMENTS, CORP. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39252 98-1515192 (State or Other Jurisdiction (Commission File Nu |
|
| October 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Clover Health Investments, Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 18914F103 (CUSIP Number) September 30, 2021 (Date of event which requires filing of this statement) Check the appropriate box to design |
